Literature DB >> 6778345

Immunologic response to pneumococcal polysaccharide vaccine in infants.

J L Sloyer, J H Ploussard, L J Karr, G D Schiffman.   

Abstract

The serum antibody response to purified pneumococcal capsular polysaccharides (PCP) was detrmined in four groups of infants ranging in age from 3 to 24 months. Group 1 consisted of eight infants immunized with an octavalent vaccine containing serotypes 1, 3, 6, 7, 14, 18, 19 and 23 (PCP-8). Group 1 received 25 microgram of each serotype at 3-6 months of age and again at 18-24 months. The antibody response after the second immunization was compared to a group of nine patients receiving a primary immunization at 18-24 months and to a group of ten age-matched controls receiving saline placebo. There were no significant differences in mean serum antibody levels between the two groups receiving the PCP-8. A fourth group of 44 infants between 6 and 21 months of age received either PCP-7 or PCP-8 and were followed for two years, at which time simultaneous injections of both vaccines were administered. Types 2, 3, 7, and 8 were most immunogenic but levels six months after immunization were approximately the same as for unimmunized controls with the exception of serotypes 3 and 7 which persisted for about two years. The class of antibody induced either by natural infection or by immunization was preferentially IgG and it was more often induced by the former. There were no significant differences between the serotypes of pneumococci isolated from nasopharyngeal cultures regardless of which vaccine was administered. Finally, the least immunogenic serotypes include 4, 6, 14, 19, and 23 and these are the only serotypes thus far associated with otitis media after immunization. The results suggest that PCP do not induce a lasting immune tolerance at the dose administered in this study; PCP are not very immunogenic in the young infant; PCP antibody tends to rise naturally; IgG antibody is preferentially induced; nasopharyngeal colonization is not altered by PCP immunization; and an association may exist between PCP immunogenicity and subsequent onset of otitis media.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6778345     DOI: 10.1177/00034894800890s382

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol Suppl        ISSN: 0096-8056


  6 in total

1.  Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci.

Authors:  Liselotte Högberg; Patricia Geli; Håkan Ringberg; Eva Melander; Marc Lipsitch; Karl Ekdahl
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

Review 2.  Paediatric pneumococcal disease in Central Europe.

Authors:  R Prymula; R Chlibek; I Ivaskeviciene; A Mangarov; Zs Mészner; P Perenovska; D Richter; N Salman; P Simurka; E Tamm; G Tešović; I Urbancikova; V Usonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-11       Impact factor: 3.267

3.  Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea.

Authors:  W S Pomat; D Lehmann; R C Sanders; D J Lewis; J Wilson; S Rogers; T Dyke; M P Alpers
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

4.  Severity of infections in IgA deficiency: correlation with decreased serum antibodies to pneumococcal polysaccharides and decreased serum IgG2 and/or IgG4.

Authors:  M A French; K A Denis; R Dawkins; J B Peter
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

Review 5.  Capsular polysaccharide vaccines today.

Authors:  P H Mäkelä
Journal:  Infection       Date:  1984       Impact factor: 3.553

Review 6.  Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Authors:  Marta C Nunes; Shabir A Madhi
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.